{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Etarotene (Ro 15-1570) is an arotinoid sulfone. Etarotene inhibits RNase P, a ribonucleoprotein that endonucleolytically cleaves all tRNA precursors to produce the mature 5' end, thereby affecting tRNA biogenesis. Etarotene has antikeratinizing potential. It was undergoing phase III clinical trials with Roche in the US for the treatment of psoriasis and other skin.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Toripristone has a high inhibiting activity against the cortisol receptors. Toripristone enhanced the antibacterial activities of the sparfloxacin in combination with ethambutol in the treatment of M. avium complex infections. Also, toripristone is a glucocorticoid type II receptor and progesterone receptor antagonist. Toripristone treatment was estimated to selectively occupy approximately 50% of glucocorticoid receptors in rat brain.
Status:
Investigational
Source:
NCT02272478: Phase 2/Phase 3 Interventional Unknown status Acute Myeloid Leukaemia
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ganetespib (formerly called STA-9090) is a novel, injectable resorcinolic triazolone small molecule inhibitor of Hsp90, developed by Synta Pharmaceuticals. Ganetespib inhibits the growth of many tumor types in vitro and in vivo including AML, ALL, CML, NHL, neuroblastoma, Ewing sarcoma, rhabdoid cancer, rhabdomyosarcoma, melanoma, and carcinomas of the breast, lung, prostate, bladder and colon7-10,14-27. Ganetespib has being studied in multiple adult oncology indications. The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. Ganetespib has been studied in 5 completed Synta-sponsored clinical trials (Studies 9090-02, 9090-03, 9090-04, 9090-05, and 9090-07) and 3 completed Synta-sponsored studies in normal healthy volunteers (9090-12, 9090-13, and 9090-15). Ganetespib is currently being studied in 6 Synta-sponsored clinical trials. Studies include: one Phase 1 study, three Phase 2 studies, one Phase 2b study, and one Phase 3 study. Ganetespib is also being studied in 24 Investigator Sponsored Trials (ISTs)
Status:
Investigational
Source:
NCT04028492: Phase 3 Interventional Recruiting Idiopathic Gastroparesis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Tradipitant is a neurokinin 1 receptor antagonist. The dose of 50 mg of tradipitant given orally for 4 weeks was not superior to placebo in reducing itch intensity in patients with atopic dermatitis. However, in a subsequent study, in which a higher dose (85 mg) was administered for 8 weeks, significant antipruritic effect compared with placebo was recorded. Tradipitant is in phase III clinical trial for the treatment of atopic dermatitis and gastroparesis. Vanda Pharmaceuticals plans a phase III trial in Motion Sickness in 2019.
Status:
Investigational
Source:
INN:pyrophendane [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Pyrophenindane is pyrrolidylmethyl-substituted arylindan patented by Mead Johnson & Co. as antispasmodic agent. Pyrophenindane have potent activity in the prevention of reserpine-induced ptosis in mice, a test for antidepressant activity.
Status:
Investigational
Source:
NCT01702467: Phase 1 Interventional Completed Alzheimer's Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02945774: Not Applicable Interventional Recruiting Frontotemporal Dementia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03340168: Not Applicable Interventional Unknown status PHARMACOKINETICS
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Cyprazepam is a benzodiazepine tranquilizer, developed by Warner-Lambert Pharmaceutical Company in the 1960s. The combination of cyprazepam with pentaerythrityl tetranitrate was found advantageous for the treatment of angina pectoris.
Status:
Investigational
Source:
INN:leiopyrrole [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LEIOPYRROLE is an antispasmodic agent.
